Clinical trials: Moderate Asthma
Asthma
Efficacy and Safety Study of GSK3772847 in Subjects With Moderately Severe Asthma
GSK3772847, an anti-interleukin (IL)33 receptor monoclonal antibody, is a novel treatment for asthma. This is a phase 2a study which aims to evaluate efficacy, safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD)…
- Trial name
- NCT03207243
- Testing
- GSK3772847, Fluticasone propionate/salmeterol, Fluticasone propionate
- Where
- 64 sites in United States, Australia and 4 more
- Volunteers
- 165 people
- Sponsor
- GlaxoSmithKline
Asthma
Efficacy and Tolerability of Maintenance Treatment With Asmanex Twisthaler Versus Placebo in Mild/Moderate Persistent Asthmatics (Study P04654)(TERMINATED)
This is a randomized, multicenter, placebo-controlled, double-blind, parallel-group study evaluating Asmanex Twisthaler 220 mcg once daily (QD) in the evening (PM) compared with "Asmanex" Placebo QD PM for 12 weeks.
- Trial name
- NCT00442351
- Testing
- Asmanex twisthaler
- Volunteers
- 26 people
- Sponsor
- Organon and Co
Asthma
Acute Effect of Mometasone on Beta-adrenergic Airway and Airway Vascular Relaxation in Severe Asthma
Glucocorticosteroids inhibit the disposal of organic cations by blocking organic cation transporters expressed by non-neuronal cells, thereby interfering with the inactivation of the organic cations by intracellular enzymes.
- Trial name
- NCT01210170
- Testing
- mometasone 400 mcg, mometasone 200 mcg
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Miami
Allergic Asthma
The Tolerability and Effects of AZD8848 in Allergic Asthma Subjects Challenged With Inhaled Allergen
AZD8848 is a new drug that is being tested for the treatment of asthma and allergic rhinitis (hayfever). This study will be in two parts and will include 59 asthmatic patients in total.
- Trial name
- NCT00999466
- Testing
- AZD8848
- Where
- 2 sites in United Kingdom
- Volunteers
- 60 people
- Sponsor
- AstraZeneca
Eosinophilic Asthma
Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma
The primary objective of the study is to characterize the efficacy of reslizumab treatment, at a dosage of 3.0 milligrams per kilogram (mg/kg) every 4 weeks for a total of 4 doses, in improving pulmonary function in relation to…
- Trial name
- NCT01508936
- Testing
- Reslizumab
- Where
- 66 sites in United States
- Volunteers
- 511 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Asthma
A Study to Evaluate the Effect of Dupilumab on Exercise Capacity in Adult Patients With Asthma
The primary objective of the study is to demonstrate that dupilumab treatment improves exercise capacity in patients with moderate-to-severe asthma.
- Trial name
- NCT04203797
- Testing
- dupilumab
- Where
- 30 sites in United States, France and 3 more
- Volunteers
- 40 people
- Sponsor
- Regeneron Pharmaceuticals
Asthma
Efficacy and Safety of 3 Doses of Tiotropium Compared to Placebo in Adolescents (12 to 17 Yrs) With Moderate Asthma
The primary objective of this trial is to evaluate the efficacy and safety of tiotropium 1.25 mcg (2 actuations of 0.625 mcg), tiotropium 2.5 mcg (2 actuations of 1.25 mcg) and tiotropium 5 mcg (2 actuations of 2.5 mcg) once…
- Trial name
- NCT01122680
- Testing
- Tiotropium bromide
- Where
- 19 sites in United States, Germany and 3 more
- Volunteers
- 105 people
- Sponsor
- Boehringer Ingelheim
Asthma
A Comparison of Critical Errors, Overall Errors, Training/Teaching Time, and Preference Attributes of the ELLIPTA Versus BREEZHALER Dry Powder Inhalers (DPIs) in Adult Participants With Asthma
This study aims to provide data in adult participants with mild to moderate asthma to assist healthcare professionals (HCPs) in assessing various attributes of ELLIPTA and BREEZHALER DPIs, by comparing the incidence of critical…
- Trial name
- NCT04813354
- Testing
- ELLIPTA, BREEZHALER
- Where
- 3 sites in Netherlands
- Volunteers
- 114 people
- Sponsor
- GlaxoSmithKline
Moderate-to-severe Allergic Asthma
A Study to Assess the Impact of Omalizumab on Exercise Capacity, Physical Activity, and Sleep Quality in Participants With Moderate to Severe Allergic Asthma
This study will assess the effect of omalizumab on exercise capacity, physical activity, and sleep quality after 24 weeks of treatment in participants with moderate to severe allergic asthma.
- Trial name
- EDURO (NCT04195958)
- Testing
- Omalizumab
- Where
- 12 sites in United States
- Volunteers
- 3 people
- Sponsor
- Genentech, Inc.
Asthma
Study to Evaluate the Efficacy and Safety of Benralizumab in Adult Patients With Mild to Moderate Persistent Asthma
The purpose of this trial is to confirm the safety and clinical benefit of benralizumab administration in asthma patients with mild to moderate persistent asthma in order to gain an understanding of the benefit/risk of…
- Trial name
- NCT02322775
- Testing
- Benralizumab
- Where
- 57 sites in United States, Canada and 4 more
- Volunteers
- 211 people
- Sponsor
- AstraZeneca
Moderate to Severe Asthma
Study to Assess the Effect of Tezepelumab on the Immune Response to Influenza Vaccination in Participants With Asthma
This is a Phase 3b, multicenter, randomized, double-blind, parallel group, placebo-controlled study designed to investigate the potential effect of tezepelumab (210 mg subcutaneous [SC] every 4 weeks [Q4W]) on antibody responses…
- Trial name
- VECTOR (NCT05062759)
- Testing
- Tezepelumab
- Where
- 15 sites in United States
- Volunteers
- 70 people
- Sponsor
- AstraZeneca
Asthma
A Randomised, Double- Blind, Placebo Controlled, Cross-over Efficacy and Safety Comparison of Tiotropium 5 µg Once Daily and Tiotropium 2.5 µg Twice Daily for Four Weeks in Patients With Moderate Persistent Asthma
Rationale for the current trial is to demonstrate 24 hour bronchodilator efficacy and safety of tiotropium 5 µg administered once daily (in the evening) which is regarded beneficial for the compliance and convenience of the…
- Trial name
- NCT01152450
- Testing
- Tiotropium 2.5 µg b.i.d, Tiotropium 5 µg q.d.
- Where
- 15 sites in Austria, Czechia and 3 more
- Volunteers
- 94 people
- Sponsor
- Boehringer Ingelheim
Asthma
An Efficacy Study Comparing SYMBICORT® Pressurised Metered Dose Inhaler (pMDI) With Budesonide Hydrofluoroalkanes (HFA) pMDI, in Hispanic Subjects With ICS Dependent Asthma
The purpose of this study is to determine the effectiveness and safety of SYMBICORT® pMDI (a medication approved by the Food and Drug Administration(FDA)) in the Hispanic population.
- Trial name
- NCT00419757
- Testing
- Budesonide/formoterol (SYMBICORT) pMDI, Budesonide HFA pMDI
- Where
- 39 sites in United States, Puerto Rico
- Volunteers
- 558 people
- Sponsor
- AstraZeneca
Asthma
Dose Ranging Study of Amlitelimab in Adult Participants With Moderate-to-severe Asthma
This was a parallel, Phase 2, global, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, four-arms study for treatment.
- Trial name
- TIDE-asthma (NCT05421598)
- Testing
- Amlitelimab
- Where
- 113 sites in United States, Argentina and 12 more
- Volunteers
- 437 people
- Sponsor
- Sanofi
Asthma
Efficacy and Safety of Tiotropium and Salmeterol in Moderate Persistent Asthma Patients Homozygous for B16-Arg/Arg
This is a 16 week multicentre, multinational, randomised, double-blind, double-dummy, placebo-controlled, parallel group study to evaluate the long-term efficacy and safety of tiotropium compared to salmeterol in moderate…
- Trial name
- NCT00350207
- Testing
- Tiotropium bromide, Salmeterol xinafoate
- Where
- 109 sites in Austria, Belgium and 12 more
- Volunteers
- 388 people
- Sponsor
- Boehringer Ingelheim
Asthma
Chronic Dosing Cross-Over Study to Assess the Efficacy and Safety of Glycopyrronium (PT001) in Adult Subjects With Intermittent Asthma or Mild to Moderate Persistent Asthma
A Randomized, Double-Blind, Chronic Dosing (14 days), 5-Period, 7-Treatment, Placebo-Controlled, Incomplete Block, Cross-Over, Multi-center, Dose-ranging Study to Assess the Efficacy and Safety of Glycopyrronium MDI (PT001)…
- Trial name
- NCT02433834
- Testing
- Glycopyrronium MDI, Serevent Diskus 50 μg
- Where
- 43 sites in United States
- Volunteers
- 248 people
- Sponsor
- Pearl Therapeutics, Inc.
Asthma
Use of Dexamethasone in Pediatric Asthma Exacerbations
The purpose of this study is to compare the efficacy of a single dose of dexamethasone vs. two doses of dexamethasone in mild and moderate asthma exacerbations pediatric patients.
- Trial name
- NCT02192827
- Testing
- Dexamethasone Sodium Phosphate Injection
- Where
- United States
- Volunteers
- 318 people
- Sponsor
- University at Buffalo
Asthma
A Comparison of Mometasone Furoate DPI Versus Budesonide DPI in Budesonide DPI in Asthmatics (Study P04880)
This study will be an open-label, parallel-group comparison of Mometasone Furoate Dry Powder Inhaler (MF-DPI) 200 mcg once daily in the evening with two puffs vs.
- Trial name
- NCT00442117
- Testing
- mometasone furoate dry powder inhaler, Budesonide DPI
- Volunteers
- 180 people
- Sponsor
- Organon and Co
Asthma
First Time in Human (FTIH) Study to Evaluate Safety, Tolerability, Immunogenicity, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK3511294 Administered Subcutaneously (SC) in Subjects With Mild to Moderate Asthma
GSK3511294 is a humanized monoclonal antibody antagonist of Interleukin (IL)-5 which is known to block binding of IL-5 to the IL-5 receptor complex, causing a reduction in the circulating population of eosinophils.
- Trial name
- NCT03287310
- Testing
- GSK3511294, Salbutamol/albuterol
- Where
- 5 sites in Germany, United Kingdom
- Volunteers
- 50 people
- Sponsor
- GlaxoSmithKline
Asthma
Tolerability and PK of Submicron Budesonide in Children 4 to 11 Years Old With Mild-To-Moderate Stable Asthma
This Phase 2 study was to investigate the tolerability of unit dose budesonide (MAP0020) at three doses in pediatric volunteers with a diagnosis and history of mild-to-moderate stable asthma and evaluate the pharmacokinetic…
- Trial name
- NCT00995904
- Testing
- 84ug MAP0020, 42ug MAP0020, 21ug MAP0020
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Allergan